Profile data is unavailable for this security.
About the company
AN2 Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. Its initial candidate is epetraborole, which is a potential once-daily, oral treatment with a novel mechanism of action for patients with non-tuberculous mycobacterial (NTM) lung disease, a rare, chronic, and progressive infectious disease caused by bacteria known as mycobacteria, which leads to irreversible lung damage and can be fatal. Epetraborole is designed to produce broad-spectrum antimycobacterial activity through inhibition of an essential and universal step in bacterial protein synthesis. Epetraborole is an investigational, boron-containing, orally bioavailable, small molecule inhibitor of bacterial leucyl-tRNA synthetase (LeuRS), an enzyme that catalyzes the attachment of leucine to transfer RNA (tRNA), molecules, an essential step in protein synthesis.
- Revenue in USD (TTM)0.00
- Net income in USD-33.99m
- Incorporated2017
- Employees22.00
- LocationAN2 Therapeutics Inc1300 El Camino Real, Suite 100MENLO PARK 94025United StatesUSA
- Phone+1 (650) 331-9090
- Websitehttps://www.an2therapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fibrobiologics Inc | 0.00 | -18.65m | 26.31m | 15.00 | -- | 4.21 | -- | -- | -0.444 | -0.444 | 0.00 | 0.0925 | 0.00 | -- | -- | 0.00 | -143.08 | -- | -322.07 | -- | -- | -- | -- | -- | -- | -12.08 | 0.00 | -- | -- | -- | -67.06 | -- | -- | -- |
| Axe Compute Inc | 728.20k | -84.01m | 26.68m | 23.00 | -- | -- | -- | 36.63 | -120.02 | -120.66 | 1.29 | -100.94 | 0.1369 | 1.34 | 2.97 | 31,660.87 | -1,579.84 | -85.09 | -- | -113.42 | 50.24 | 61.31 | -11,536.93 | -1,267.27 | 0.0134 | -0.1392 | -- | -- | -0.2384 | 2.84 | 9.63 | -- | -18.60 | -- |
| LAMY | 0.00 | 106.70k | 27.30m | -- | 28.43 | -- | 224.86 | -- | 0.0137 | 0.0137 | 0.00 | -0.0045 | 0.00 | -- | -- | -- | 763.23 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -67.39 | -- | 299.15 | -- | -- | -- |
| Raphael Pharmaceutical Inc | 0.00 | -1.40m | 27.48m | 0.00 | -- | -- | -- | -- | -0.0723 | -0.0723 | 0.00 | -0.0644 | 0.00 | -- | -- | -- | -4,831.04 | -- | -- | -- | -- | -- | -- | -- | -- | -86.56 | -- | -- | -- | -- | -13.02 | -- | -- | -- |
| VolitionRX Ltd | 1.47m | -22.88m | 27.52m | 85.00 | -- | -- | -- | 18.69 | -0.229 | -0.229 | 0.0147 | -0.316 | 0.1539 | -- | 4.74 | 17,317.88 | -241.07 | -122.29 | -- | -283.19 | -- | -- | -1,566.40 | -5,826.45 | -- | -15.03 | -- | -- | 59.10 | 135.30 | 23.65 | -- | 2.34 | -- |
| Aeon Biopharma Inc | 0.00 | -3.00k | 27.58m | 5.00 | 0.2238 | -- | 353.59 | -- | 4.87 | 4.87 | 0.00 | -1.71 | 0.00 | -- | -- | 0.00 | -0.0471 | -- | -- | -- | -- | -- | -- | -- | -- | -5.95 | -- | -- | -- | -- | 110.92 | -- | -- | -- |
| IGC Pharma Inc | 1.11m | -6.45m | 27.69m | 70.00 | -- | 3.28 | -- | 25.04 | -0.078 | -0.078 | 0.0134 | 0.088 | 0.11 | 0.5489 | 26.02 | 15,800.00 | -64.10 | -51.04 | -81.62 | -56.88 | 46.20 | 43.57 | -582.82 | -1,150.02 | 0.889 | -- | 0.0165 | -- | -5.50 | -20.77 | 45.22 | -- | -35.93 | -- |
| Neurosense Therapeutics Ltd | 0.00 | -8.66m | 28.39m | 15.00 | -- | -- | -- | -- | -0.361 | -0.361 | 0.00 | -0.0211 | 0.00 | -- | -- | 0.00 | -491.23 | -145.64 | -- | -198.79 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -1.02 | -- | -15.59 | -- |
| Werewolf Therapeutics Inc | 0.00 | -72.84m | 28.40m | 39.00 | -- | 0.934 | -- | -- | -1.62 | -1.62 | 0.00 | 0.6264 | 0.00 | -- | -- | 0.00 | -66.32 | -33.10 | -76.84 | -36.81 | -- | -- | -- | -593.05 | -- | -54.29 | 0.4829 | -- | -90.55 | -- | -88.70 | -- | -0.919 | -- |
| Dyadic International Inc | 3.34m | -7.35m | 28.56m | 6.00 | -- | 10.95 | -- | 8.55 | -0.2371 | -0.2371 | 0.1077 | 0.072 | 0.2974 | -- | 5.27 | 557,033.30 | -65.38 | -46.12 | -89.89 | -51.96 | 31.54 | 35.01 | -219.86 | -335.59 | -- | -34.44 | 0.6579 | -- | 20.58 | 15.77 | 14.51 | -- | -- | -- |
| AN2 Therapeutics Inc | 0.00 | -33.99m | 29.05m | 22.00 | -- | 0.4805 | -- | -- | -1.13 | -1.13 | 0.00 | 2.21 | 0.00 | -- | -- | 0.00 | -41.21 | -53.41 | -45.91 | -58.50 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 20.72 | -- | -- | -- |
| Tempest Therapeutics Inc | 0.00 | -36.05m | 29.69m | 24.00 | -- | 1.57 | -- | -- | -10.40 | -10.40 | 0.00 | 1.43 | 0.00 | -- | -- | 0.00 | -141.49 | -63.01 | -215.46 | -80.57 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -41.88 | -- | 1.85 | -- |
| CEL-SCI Corp | 0.00 | -23.81m | 30.03m | 43.00 | -- | 2.68 | -- | -- | -5.24 | -5.24 | 0.00 | 1.32 | 0.00 | -- | -- | -- | -97.99 | -72.20 | -125.06 | -80.91 | -- | -- | -- | -- | 1.35 | -41.06 | 0.3996 | -- | -- | -- | 7.86 | -- | -57.33 | -- |
| Rein Therapeutics Inc | 0.00 | -58.89m | 30.23m | 11.00 | -- | 24.40 | -- | -- | -2.63 | -2.63 | 0.00 | 1.84 | 0.00 | -- | -- | 0.00 | -74.57 | -64.62 | -80.38 | -71.24 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -299.71 | -- | -- | -- |
| Lantern Pharma Inc | 0.00 | -18.92m | 30.31m | 24.00 | -- | 3.12 | -- | -- | -1.75 | -1.75 | 0.00 | 0.8684 | 0.00 | -- | -- | 0.00 | -86.16 | -32.94 | -104.31 | -34.72 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -30.20 | -- | 17.11 | -- |
| Harvard Apparatus Regenertv Tchnlgy Inc | 743.00k | -6.53m | 30.39m | 8.00 | -- | 19.56 | -- | 40.90 | -0.4029 | -0.4029 | 0.0459 | 0.0905 | 0.1891 | 9.21 | 371.50 | 92,875.00 | -166.09 | -292.39 | -227.59 | -1,068.06 | 16.29 | -- | -878.20 | -6,677.86 | 1.83 | -- | 0.00 | -- | 317.48 | -- | 14.30 | -- | -- | -- |
Data as of Mar 04 2026. Currency figures normalised to AN2 Therapeutics Inc's reporting currency: US Dollar USD
22.08%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Almitas Capital LLCas of 31 Dec 2025 | 1.48m | 5.40% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 935.03k | 3.41% |
| Stonepine Capital Management LLCas of 31 Dec 2025 | 627.67k | 2.29% |
| Peapod Lane Capital LLCas of 31 Dec 2025 | 593.40k | 2.17% |
| The Bank of Nova Scotia (Private Banking)as of 31 Dec 2025 | 459.19k | 1.68% |
| Landscape Capital Management LLCas of 31 Dec 2025 | 431.76k | 1.58% |
| BMO Asset Management Corp.as of 31 Dec 2025 | 422.08k | 1.54% |
| Bank of America, NA (Private Banking)as of 31 Dec 2025 | 385.29k | 1.41% |
| Aldebaran Capital LLCas of 31 Dec 2025 | 376.77k | 1.38% |
| Renaissance Technologies LLCas of 31 Dec 2025 | 338.60k | 1.24% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
